Regulatory Action Against Ranbaxy

These facilities are now owned by Sun Pharmaceutical.

Consent Decree for Toansa, India, Facility
Import Alert and Consent Decree for Mohali, India, Facility
  • FDA Press Release: FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy’s Mohali, India, plant and issues import alert (9/16/2013)
Department of Justice Action Against Ranbaxy
  • DOJ News Release: Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, CGMP Violations and False Statements to the FDA (5/13/2013)
Consent Decree for Paonta Sahib, Batamandi, and Dewas, India, Facilities and Ohm Laboratories in Gloversville, N.Y.
  • FDA News Release: Department of Justice files consent decree of permanent injunction against Ranbaxy (1/25/2012)
Application Integrity Policy Action for Paonta Sahib, India, Facility
Import Alert for Dewas and Paonta Sahib, India, Facilities

Additional Warning Letters

Back to Top

Page Last Updated: 05/15/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English